FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| OMB APPROVAL | | | | | | | | |
|------------------------|-----------|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | |
| Estimated average burd | len | | | | | | | |
| hours per response: | 0.5 | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* LANGE LOUIS G | | | | 2. Issuer Name and Ticker or Trading Symbol Audentes Therapeutics, Inc. [BOLD] | | | | | | | | | | Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner | | | | | | | |
|---|---|--|---|--|--|--------------------------------------|-------------------------|---|------------------------|------|--------------------------------------|---|---|---|--|--|--|---|---|--|--|
| (Last) | (Fir | , | Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 12/22/2017 | | | | | | | | | | | | er (give | (give title O | | er (specify ow) | | |
| C/O AUDENTES THERAPEUTICS, INC. 600 CALIFORNIA STREET, 17TH FLOOR | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | | ′ I | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person | | | | | | | | |
| (Street) SAN FRANCISCO CA 94108 | | | | | | | | | | | | | | | Form filed by More than One Reporting Person | | | | | | |
| (City) | (St | | Zip) | | | | | | | | | | | | | | | | | | |
| | | | le I - Non-Deriv | | | _ | | uire | _ | | | | | _ | | | | | | | |
| Da | | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | | | 3. Transactio Code (Inst 8) | | | | | quired (A) or (Instr. 3, 4 and 5) | | 5. Amount of Securities Beneficially Owned | | ly | 6. Ownership Form: Direct (D) or Indirect (I) | | 7. Nature of Indirect Beneficial Ownership | | | |
| | | | | | | G | Code V | | Amo | unt | (A) or (D) | or Price | | Following Reported Transaction(s) (Instr. 3 and 4) | | | (Instr. 4) | | (Instr. 4) | | |
| Common | Stock | | 12/22/2017 | | | | S ⁽¹⁾ | | 15, | ,000 | D | \$3 | 0.8773(2 | 42 | 25,7 | 99 | Γ |) | | | |
| Common | Stock | | 12/22/2017 | | | | S ⁽¹⁾ | | 1,0 | 000 | D | \$3 | 0.9019 ⁽³ | 1 | 0,55 | 55 | I | i N | By Adrienne M. MacMillan Revocable Trust ⁽⁴⁾ | | |
| Common | Stock | | 12/22/2017 | | | | S ⁽¹⁾ | | 1,0 | 000 | D | \$3 | 0.8581 ⁽³ | 2 | 1,67 | 78 | I | I | By Amygdala Lange Trust ⁽⁵⁾ | | |
| Common Stock | | 12/22/2017 | | | | S ⁽¹⁾ | | 1,0 | 000 | D | \$30.8727(6) | | 4,558 | | 8 | I | | By Lange Minors' Trust ⁽⁷⁾ | | | |
| Common Stock | | | | | | | | | | | | | 87,343 | | 43 | I | | By Asset Management Ventures Fund, L.P. ⁽⁸⁾ | | | |
| | | Та | able II - Derivat (e.g., p | | | | | | | | | | | | ed | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | e (Month/Day/Year) | Execution Date, | Transaction (Code (Instr. I | | | | 6. Date Exe Expiration (Month/Day | | | | Amount of Securities Underlying Derivative Security (Inst 3 and 4) | | 8. Price of Derivar Securit (Instr. | derivat tive Securit ty Benefic | | ies cially ing ed ction(s) | | ct (Instr. 4) | | |
| | | | | Code V (| | .) | (D) | Date Exerci | Expirati sable Date | | | Title | Amount or Number of Shares | | | | | | | | |

Explanation of Responses:

- 1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- 2. Represents the weighted average sale price. The lowest price at which shares were sold was \$30.44 and the highest price at which shares were sold was \$31.20. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (6) to this Form 4.
- 3. Represents the average weighted sale price. The lowest price at which shares were sold was \$30.66 and the highest price at which shares were sold was \$31.13.

- 4. The reporting person's domestic partner is the trustee of the Adrienne M. MacMillan Revocable Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
- 5. The reporting person's domestic partner is the trustee of the Amygdala Lange Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
- 6. Represents the average weighted sale price. The lowest price at which shares were sold was \$30.66 and the highest price at which shares were sold was \$31.10.
- 7. The reporting person's domestic partner is the trustee of the Lange Minors' Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
- 8. The reporting person is a general partner of Asset Management Ventures Fund, L.P. ("AMVF L.L.P."), and has shared voting and dispositive power over the shares held by AMVF L.L.P. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

Remarks:

/s/ Thomas Soloway as attorney-in-fact for Louis 12/26/2017 Lange, M.D., Ph.D.

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.